The document discusses point-of-care (POC) testing, which involves diagnostic tests performed near patients outside of centralized laboratories. It estimates the global POC diagnostics market was $17 billion in 2014 and is projected to grow to $18.7 billion by 2016. Key drivers of growth include rapid results to inform immediate treatment decisions, expanded test menus, and advances enabling quantitative lab-quality results. Major diseases addressed by POC solutions discussed are colorectal cancer, cardiovascular disease, and diabetes.
New technologies in point-of-care nucleic acid testsPaolo Dametto
An adapted version of my technical Journal club on a new technology that detects DNA amplification using a pH-sensing system. The implications for point-of-care nucleic acid tests are significant.
Point of care testing market and forecast to 2016 global analysisRenub Research
Renub Research (http://www.renub.com/report/point-of-care-testing-market-and-forecast-to-2016-global-analysis-88) has announced the addition of the "Point of Care Testing Market and Forecast to 2016: Global Analysis" report to its offering
Point of Care Testing Market and Forecast to 2016: Global Analysis - Market Overview
The concept of Point of Care Testing (POCT), also known as bedside, near-patient testing and decentralized testing, relates to tests that are conducted by clinical operators at the site of patient care where immediate medical action is taken on the results. The fact that point of care (POCT) represents a departure from conventional laboratory medicine has created new opportunities in the field of diagnostics industry. Technical advancements over recent years have helped point of care testing (POCT) to grow with double digit CAGR from 2009 to 2011 and evolve into a vital diagnostic tool. It is predicted that point of care testing market will be approximately US$ 25 Billion by 2016.
Blood glucose test controls a lion’s market share of around 70% for the year 2011 and it is expected to continue its dominance till 2016. Rest of all the others point of care tests market share covered in this report are in single digit. Infectious disease testing market is expected to double by 2016 from its market of 2011. As countries are making the healthcare more and more accessible to people, the demand for various point of care testing is keep on rising. The point of care testing market has become an established sector worldwide and will continue to provide vital contribution in in-vitro diagnostics industry.
This 83 page report contains 26 Figures and 12 Tables provides a comprehensive analysis of the emerging point of care tests market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Renub Research report entitled “Point of Care Testing Market and Forecast to 2016: Global Analysis” report also provides market landscape and market share information in the point of care testing market. The report brings together major merger & acquisition, distribution agreement, licensing deals information in point of care testing market. The report also entails major drivers and challenges of point of care testing market.
10 Point of Care Test Segments Covered in this Report
Blood Glucose Testing, Cardiac Marker Testing, Lipid Panel/Cholesterol Testing, Blood Coagulation Testing, Infectious Disease Testing, Urinalysis Testing, Drug of Abuse Testing, Fecal Occult Blood Testing, Pregnancy & Fertility Testing and Tumor Marker Testing
Avoiding Common Pitfalls in Cell and Gene Therapy TrialsMedpace
Our experts will dive into case studies explaining the issues that arose with past projects, and how these studies got back on track. The knowledge gained from these experiences accelerate CGT development by avoiding potential pitfalls and getting ahead of regulatory and operational issues. Our team will walk you through the delays associated with these pitfalls and how to avoid them.
COVID-19 Product Development and Clinical Trials: Considerations from Europea...Medpace
Join experts from Medpace’s regulatory and operational teams in this webinar as they provide insights and considerations on how to accelerate product development for COVID-19 during different stages
New technologies in point-of-care nucleic acid testsPaolo Dametto
An adapted version of my technical Journal club on a new technology that detects DNA amplification using a pH-sensing system. The implications for point-of-care nucleic acid tests are significant.
Point of care testing market and forecast to 2016 global analysisRenub Research
Renub Research (http://www.renub.com/report/point-of-care-testing-market-and-forecast-to-2016-global-analysis-88) has announced the addition of the "Point of Care Testing Market and Forecast to 2016: Global Analysis" report to its offering
Point of Care Testing Market and Forecast to 2016: Global Analysis - Market Overview
The concept of Point of Care Testing (POCT), also known as bedside, near-patient testing and decentralized testing, relates to tests that are conducted by clinical operators at the site of patient care where immediate medical action is taken on the results. The fact that point of care (POCT) represents a departure from conventional laboratory medicine has created new opportunities in the field of diagnostics industry. Technical advancements over recent years have helped point of care testing (POCT) to grow with double digit CAGR from 2009 to 2011 and evolve into a vital diagnostic tool. It is predicted that point of care testing market will be approximately US$ 25 Billion by 2016.
Blood glucose test controls a lion’s market share of around 70% for the year 2011 and it is expected to continue its dominance till 2016. Rest of all the others point of care tests market share covered in this report are in single digit. Infectious disease testing market is expected to double by 2016 from its market of 2011. As countries are making the healthcare more and more accessible to people, the demand for various point of care testing is keep on rising. The point of care testing market has become an established sector worldwide and will continue to provide vital contribution in in-vitro diagnostics industry.
This 83 page report contains 26 Figures and 12 Tables provides a comprehensive analysis of the emerging point of care tests market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Renub Research report entitled “Point of Care Testing Market and Forecast to 2016: Global Analysis” report also provides market landscape and market share information in the point of care testing market. The report brings together major merger & acquisition, distribution agreement, licensing deals information in point of care testing market. The report also entails major drivers and challenges of point of care testing market.
10 Point of Care Test Segments Covered in this Report
Blood Glucose Testing, Cardiac Marker Testing, Lipid Panel/Cholesterol Testing, Blood Coagulation Testing, Infectious Disease Testing, Urinalysis Testing, Drug of Abuse Testing, Fecal Occult Blood Testing, Pregnancy & Fertility Testing and Tumor Marker Testing
Avoiding Common Pitfalls in Cell and Gene Therapy TrialsMedpace
Our experts will dive into case studies explaining the issues that arose with past projects, and how these studies got back on track. The knowledge gained from these experiences accelerate CGT development by avoiding potential pitfalls and getting ahead of regulatory and operational issues. Our team will walk you through the delays associated with these pitfalls and how to avoid them.
COVID-19 Product Development and Clinical Trials: Considerations from Europea...Medpace
Join experts from Medpace’s regulatory and operational teams in this webinar as they provide insights and considerations on how to accelerate product development for COVID-19 during different stages
Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.
The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...Medpace
In this webinar, we explore the regulatory implications of the RACE for Children Act and what this law means for your development program, particularly with navigating the change in requirements for pediatric oncology trials. Furthermore, we explore the challenges of executing oncology trials in pediatric populations and offer insight into design and operational aspects to seamlessly execute these studies as part of your clinical development plan
Presentation by David Farber, FDA Life Science Partner at King & Spalding, about US Reimbursement.
I. Introduction
• II. FDA Approval vs. Reimbursement
• a. Different Standards
b. Clinical Evidence Needed
• III. The Three Keys to Reimbursement
A. Coverage
B. Coding
C. Payment
• IV. What’s New for 2019
• V. Reimbursement for MedTech AI Solutions
• VI. Tips for Successful Reimbursement
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
Considerations for the Next Wave of COVID-19 DevelopmentMedpace
What did we learn from the first wave of COVID-specific studies that can be applied to those studies that will follow? Medpace has gathered some of its medical and operational team experts who have been on the front-line in designing and conducting trials for SARS-CoV-2 to answer some frequently asked questions, trends they see emerging and considerations for future development.
Survival guide to stem cell research and therapiesArete-Zoe, LLC
Survival guide to stem cell research and therapies provides comprehensive guidance to publicly available resource materials, libraries and registries for people who are interested in understanding currently available treatment options involving human stem cells.
Potential: The first section explains how stem cells are currently used in research, drug testing, and therapy, and how they have to be manipulated before transfer to make any treatments possible.
Classification: Origin and ability of stem cells to differentiate into different cell types determine how different types of stem cells are typically used.
Clinical Research: In this section, we will introduce the two most important registries of clinical trials: NIH registry ClinicalTrials gov and WHO International Clinical Trials Registry Platform. A project is part of this section to give students the opportunity to get hands-on experience with collecting and collating relevant information from registries and libraries, and interpretation of the findings. Real-time interactive sessions are included to allow students to ask questions and offer additional guidance.
Patient Demand: In this section, we briefly introduce challenges relating to marketing claims, objective outcome measures, advertising strategies, and patient autonomy.
Regulatory and Legal Framework: Stem cell therapies are regulated differently in various countries around the world. In this section, we will focus on regulations that govern stem cell research and therapies in the U.S. and in the European Union. Policies on stem cell research are driven by ethical concerns relating to research that utilizes human embryos. China recently announced new ethical guidelines and new rules for its stem cell clinics, regulating both trials and treatments.
Professional Societies: The last section explains the role of professional societies in stem cell research and therapies.
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...Andrew Aijian
We conducted interviews with precision medicine KOLs to create a map of the precision medicine stakeholder landscape and identify and understand the unmet needs and pain points within precision medicine, as well as areas and scenarios of potential disruption.
EPharma day munich - RBM with EU Clinical Trials RegulationArtem Andrianov
The new EU Clinical Trials Regulation (CTR) becomes applicable not earlier than on 28th of May 2016. It introduces a number of changes in the clinical trial’s application, operations, documentation, and assessment. Although CTR is not taking the direct reference on RbM, it refers to principles of Good Clinical Practice (GCP) and Quality by Design (QbD). These principles are the underlying in RbM as well. Therefore, the author offers to apply RbM as a practical mechanism and process in order to embrace the new EU regulation.
Compliance shall never be the sole focus of GXP readiness preparations. Risks to business are numerous and varied and need to be considered in a holistic manner.
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Andrew Aijian
At DeciBio Consulting, we track the immuno-oncology (I/O) biomarker and technology landscape closely. Our analysis of biomarkers from ~1,000 immuno-oncology clinical trials and discussions with oncologists, pathologists, and KOLs reveals some key insights for diagnostic manufacturers to consider to address the I/O market.
Experts from Informa’s Medtrack, Trialtrove and Strategic Transactions teams presented a panel discussion at the recent T3 Conference in Orlando, Florida.
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.
The RACE for Children Act Will Change the Landscape for Pediatric Cancer Rese...Medpace
In this webinar, we explore the regulatory implications of the RACE for Children Act and what this law means for your development program, particularly with navigating the change in requirements for pediatric oncology trials. Furthermore, we explore the challenges of executing oncology trials in pediatric populations and offer insight into design and operational aspects to seamlessly execute these studies as part of your clinical development plan
Presentation by David Farber, FDA Life Science Partner at King & Spalding, about US Reimbursement.
I. Introduction
• II. FDA Approval vs. Reimbursement
• a. Different Standards
b. Clinical Evidence Needed
• III. The Three Keys to Reimbursement
A. Coverage
B. Coding
C. Payment
• IV. What’s New for 2019
• V. Reimbursement for MedTech AI Solutions
• VI. Tips for Successful Reimbursement
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
Considerations for the Next Wave of COVID-19 DevelopmentMedpace
What did we learn from the first wave of COVID-specific studies that can be applied to those studies that will follow? Medpace has gathered some of its medical and operational team experts who have been on the front-line in designing and conducting trials for SARS-CoV-2 to answer some frequently asked questions, trends they see emerging and considerations for future development.
Survival guide to stem cell research and therapiesArete-Zoe, LLC
Survival guide to stem cell research and therapies provides comprehensive guidance to publicly available resource materials, libraries and registries for people who are interested in understanding currently available treatment options involving human stem cells.
Potential: The first section explains how stem cells are currently used in research, drug testing, and therapy, and how they have to be manipulated before transfer to make any treatments possible.
Classification: Origin and ability of stem cells to differentiate into different cell types determine how different types of stem cells are typically used.
Clinical Research: In this section, we will introduce the two most important registries of clinical trials: NIH registry ClinicalTrials gov and WHO International Clinical Trials Registry Platform. A project is part of this section to give students the opportunity to get hands-on experience with collecting and collating relevant information from registries and libraries, and interpretation of the findings. Real-time interactive sessions are included to allow students to ask questions and offer additional guidance.
Patient Demand: In this section, we briefly introduce challenges relating to marketing claims, objective outcome measures, advertising strategies, and patient autonomy.
Regulatory and Legal Framework: Stem cell therapies are regulated differently in various countries around the world. In this section, we will focus on regulations that govern stem cell research and therapies in the U.S. and in the European Union. Policies on stem cell research are driven by ethical concerns relating to research that utilizes human embryos. China recently announced new ethical guidelines and new rules for its stem cell clinics, regulating both trials and treatments.
Professional Societies: The last section explains the role of professional societies in stem cell research and therapies.
DeciBio Perspectives on Pain Points, Unmet Needs, and Disruption in Precision...Andrew Aijian
We conducted interviews with precision medicine KOLs to create a map of the precision medicine stakeholder landscape and identify and understand the unmet needs and pain points within precision medicine, as well as areas and scenarios of potential disruption.
EPharma day munich - RBM with EU Clinical Trials RegulationArtem Andrianov
The new EU Clinical Trials Regulation (CTR) becomes applicable not earlier than on 28th of May 2016. It introduces a number of changes in the clinical trial’s application, operations, documentation, and assessment. Although CTR is not taking the direct reference on RbM, it refers to principles of Good Clinical Practice (GCP) and Quality by Design (QbD). These principles are the underlying in RbM as well. Therefore, the author offers to apply RbM as a practical mechanism and process in order to embrace the new EU regulation.
Compliance shall never be the sole focus of GXP readiness preparations. Risks to business are numerous and varied and need to be considered in a holistic manner.
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Andrew Aijian
At DeciBio Consulting, we track the immuno-oncology (I/O) biomarker and technology landscape closely. Our analysis of biomarkers from ~1,000 immuno-oncology clinical trials and discussions with oncologists, pathologists, and KOLs reveals some key insights for diagnostic manufacturers to consider to address the I/O market.
Experts from Informa’s Medtrack, Trialtrove and Strategic Transactions teams presented a panel discussion at the recent T3 Conference in Orlando, Florida.
5 Cutting-Edge Trends in Molecular DiagnosticsBruce Carlson
Despite the focus on novelty in this field, it is near 2 decades old. Yet a lot is changing. A look at a few trends that could change molecular diagnostics.
Decision makers in the healthcare field like doctors, patients and policy makers need access to clinical evidence to address issues that have bearing on the health of the population and the treatment prescribed and thereby on the financials implications of the healthcare industry.
Exact Sciences Company Presentation Baird Healthcare ConferenceExact Sciences
Exact Sciences CEO Kevin Conroy's presentation slides, featuring updates on Cologuard's commercial launch, from the 2014 Baird Healthcare Conference September 4, 2014.
An Advanced Low-cost Blood Cancer Detection SystemChristo Ananth
Christo Ananth, K. Jasmine Mystica, M. Sridharan, S. Aaron James, T. Ananth Kumar, “An Advanced Low-cost Blood Cancer Detection System”, International Journal of Early Childhood Special Education, Volume 14, Issue 05, 2022,pp. 4115-4123.
Description:
Christo Ananth et al. discussed that Blood leukemia can be diagnosed with greater precision and specificity when red blood cells are separated from young white blood cells. The only way to tell if someone has a blood disorder is to take photographs of their skin, calculate, shade, and measure them. According to the World Health Organization, leukemia is the fifth leading cause of death in the world. Early detection and identification of infection are critical to the treatment's success and outcome. It is hoped that the researchers will be able to identify and test cells that are linked to leukemia in this study. This disease can be classified according to whether or not it has immature cells and the severity of persistent or intense leukemia. A more uniform distribution of data points can be achieved by using histogram levelling and straight difference extending with morphological methods such as region opening, region closing, disintegration, and expansion. Thus, the Proposed Method is more effective than other previous methods.
Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The Company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells (CTCs) from whole blood using label-free cross-flow filtration. It is designed to be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate, and gastric cancers. This proprietary technology also powers the Company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers, and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives. The Company’s liquid biopsy products are currently generating revenue, and sales are expected to increase in the coming quarters.
What You May Have Missed at AACC 2018 White Paper - Kalorama InformationBruce Carlson
Each year the American Association for Clinical Chemistry draws tens of thousands of lab professionals and in vitro diagnostic vendors to one place. Kalorama Information was there and noted major developments at the meeting in this White Paper. Major themes of scientific sessions, new products from lab and IVD vendors are included.
The American Association of Clinical Chemistry is the largest gathering of lab professionals. It's also a time and place for IVD suppliers to show off new products. This year in Philadelphia, there were new products on display and new trends in evident.
The United States might out-perform the IVD markets of many other nations in growth as well as size. Yet there are challenges. Will ACA-based changes be shortlived? This White Paper discusses them. Based on information from our United States IVD Market.
Roundup of This Year's AACC Meeting in AtlantaBruce Carlson
The American Association of Clinical Chemistry was held this year in Atlanta, GA. Kalorama was at the meeting and notes several developments, with a particular focus on point-of-care.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Telehealth Psychology Building Trust with Clients.pptx
Point of Care Diagnostics: Revenue Growth, New Entrants, Investment
1. Point of Care: Revenue
Growth, New Entrants,
Investment
This White Paper, based on information from Kalorama
Information’s latest report on the testing market, The World Market
for Point of Care Diagnostics, estimates the market and identifies
drivers and conditions where point of care tests will be essential.
Point-of-care (POC) tests are diagnostic tests that are performed at or
near the site where the patient is located. Thus, these tests are performed in decentralized settings, outside
of centralized laboratories. Other terms used to describe POC testing include near-patient testing,
physician’s office laboratory (POL) testing, patient self-testing or patient self-management, bedside
testing, remote testing, or satellite testing. Over the years, the increasing introduction of transportable,
portable, and handheld instruments has resulted in the migration of POC testing from the hospital
environment to a range of medical environments including the workplace, home, disaster care and most
recently, convenience clinics. Some of these alternate terms
actually describe segments of the POC testing market.
The menu for point-of-care testing continues to expand.
The traditional set of POC tests includes: blood glucose testing,
blood gas and electrolytes analysis, rapid coagulation testing,
rapid cardiac markers diagnostics, drugs of abuse screening, urine
strips testing, pregnancy testing, fecal occult blood analysis,
hemoglobin diagnostics, infectious disease testing and cholesterol
screening. HgA1c, B-Type Natriuretic Peptide (BNP), whole-
blood lactate, D-Dimer, C-Reactive Protein (CRP) are among
those recently supplementing point of care test menus.
Moreover, POC test devices have contributed significantly to the growth of the overall
diagnostics market over the past 10 years. More diagnostic manufacturers have pursued CLIA waiver
status for their POC devices and CE Mark for POC or self-use. At the same time more decentralized test
venues invest in non-waived rapid tests and instruments, POC testing appears to be headed for an even
bigger role in diagnosis and monitoring patient care. New technologies are allowing POC devices to
produce quantitative lab-quality test results that can be transferred automatically to an information
system, a remote caregiver service for consultation or an electronic medical record.
10,000
11,000
12,000
13,000
14,000
15,000
16,000
17,000
18,000
19,000
2013 2014 2015 2016
POC Diagnostics Market, 2013‐2016 ($M)
2. Globally, millions of dollars are spent annually on POC diagnostic testing, both
professional and self-testing. In 2014, sales of POC testing reached $17 billion and this should
grow to 18.7 billion in 2016, as indicated on the chart on the preceding page. Below, the drivers
of the point of care testing market are discussed:
POC Industry Drivers
One of the key benefits and market drivers for the POC testing market is the ability to
have rapid results that can be used immediately for patient treatment decisions. While this is a
major benefit of POC testing, many other factors are also driving growth of this market.
Factors driving the development of POC tests include:
Patient-Focused Drivers
• Rapid results can be used immediately for patient treatment decisions in physicians offices,
and clinics.
• Demand for faster turnaround times for critical test results in hospital locations such as
emergency departments and intensive care units.
Medical/Healthcare-Related Drivers
• Introduction of POC tests for new targets such as additional infectious diseases and other
new analytes which previously could not be tested in the POC setting. Introduction of new
therapies that require rapid feedback with diagnostic tests.
• Growth of personalized healthcare and personalized medicine, and the need for rapid tests
to support this.
Technology Drivers
• Advances in miniaturization, microfluidics, and other technologies that have made it
possible to expand the numbers and types of tests that can be performed in POC settings.
Economic Drivers
• Growth in specialty clinics, retail clinics and other decentralized locations for patient care.
• Economic factors driving the need to reduce the length of patient stays in hospitals, reduce
backlog in areas such as emergency departments as patients wait for test results, etc.
Other Drivers
• Need for robust but also simple diagnostic tools for military applications outside of
military hospitals.
• Need for disaster preparedness.
• Need for robust but also simple diagnostic tools for developing countries.
3. Diseases with Point of Care Solutions
Colorectal Cancer
Colorectal cancer is the second leading cause of cancer-related deaths in the United
States There are approximately 93,090 new cases of colon cancer and 39,610 new cases of rectal
cancer estimated for 2015. Fortunately, through diligent screening and diagnostic testing, the
death rate from colorectal cancer has been dropping in both men and women. Cancer of the
colon and rectum may occur at any age but it is most prevalent over the age of 50. The 5-year
survival rate for early, localized cancers is 92% for colon cancer and 85% for rectal cancer,
whereas it remains 51% to 61% for cancer spread to adjacent organs and
lymph nodes.
Currently, there are three main types of tests that are used: fecal
occult blood tests (FOBT), fecal immunochemical tests (FIT), and stool
DNA tests (sDNA). Of these three, fecal occult blood tests are used the
most frequently – probably because they are inexpensive.
Routine colorectal cancer screening is something that tens of
millions of people in developed countries go through every few years.
Just about all developed countries have cancer screening programs that
offer free screening tests for colon cancer. After the age of 50 patients are encouraged to have a
colonoscopy every 5-10 years. Between these colonoscopies, they can use non-invasive tests
that can sometimes determine the presence of cancer or even precancers.
Cardiovascular Disease
Cardiovascular disease (CVD) continues to be a leading cause of death worldwide and
elevated cholesterol and triglycerides are among the important risk factors for this disease.
Patients are more aware of the fact that diet and exercise can alter blood levels of cholesterol as
well as drug therapy. CVD causes half of all deaths in several developed countries, and is the
major cause of adult death in many developing countries. More important, many cardiovascular
events aren't fatal but may be sufficiently debilitating to seriously affect functional ability. The
World Health Organization (WHO) estimates that 25% to 30% of the cardiovascular disease
burden arises from disabling sequelae of stroke or other forms of heart disease.
Atherosclerosis is the major cause of coronary artery disease (CAD). It is characterized by a
focal deposit of cholesterol and lipids, primarily within the intimal wall of the artery. The genesis
of plaque formation is the result of complex interactions between the components of blood and
the elements forming the vascular wall. The concept of endothelial injury is central to current
theories of atherogenesis, with endothelial injury being the leading theory for the cause of
atherosclerotic disease.
This White Paper is based
on results from Kalorama
Information's study:
The World Market for
Point of Care Diagnostics
http://www.kaloramainform
ation.com/Point-Care-POC-
9030928/
4. Roche offers the AccuCheck InstantPlus and the Reflotron cholesterol testing products. The
AccuCheck InstantPlus cholesterol test uses reflectance photometers for the quantitative
determination of cholesterol and triglycerides, with data output ports or data management
functions. Alere/Cholestech offers the LDX system, which measures the levels of total
cholesterol (TC), high-density lipoprotein, and triglycerides; calculates TC/HDL ratio; and
estimates levels of low-density lipoprotein and very-low-density lipoprotein.
Cardiac markers are biomarkers measured to evaluate heart function. Most of the early
markers were identified as enzymes. However, not all of the markers currently used are enzymes.
Physicians use cardiac markers in two ways--to diagnose a cardiac event in the hospital
emergency room or to evaluate the risk of a cardiovascular event occurring. The traditional
markers are CK-MB, troponin, and myglobin.
Ani Biotech Oy which offers the Biocard Troponin I test which is a one-step immuno
chromatographic assay for the rapid detection of cardiac specific troponin I from patient whole
blood samples. The company also offers myoglobin, MPO, hsCRP, quantitative reader, and CRP
cardiac marker tests.
Siemens offers the Stratus CS analyzer for near-patient care quantitative cardiac marker
testing from a whole blood sample in 14 minutes. The company also offers myoglobulin, CK-
MB, and cardiac troponin I tests.
Diabetes
The growing incidence of diabetes presents a health crisis in many countries. According to
the World Health Organization, 387 million people worldwide had diabetes as of 2014, with
deaths from diabetes projected to rise by more than 50% in the next 10 years. According to
International Diabetes Federation estimates, 35 million adults in Europe had diabetes in 2011 and
this is projected to increase to 43 million by 2030. This, according to WHO, is a diabetes
epidemic. People with diabetes have inadequate blood sugar control, which can lead to a range
of dangerous complications, including damage to the eyes, kidneys and heart. Approximately 4.9
million deaths worldwide are attributed to diabetes. The American Diabetes Association states
that diabetes is the primary cause of death for more than 69,000 Americans each year, and
contributes to the death of more than 234,000 Americans annually.
The first glucose meters for home use were commercialized in the early 1980s. Two models
were dominant in North America: Bayer’s Glucometer (now Bayer Diabetes Care) was
introduced in 1980 and Roche’s Accucheck meter in 1981. These two companies continue to
dominate glucose self-testing.
The situation is supported by data found in the Diabetes Atlas published by the International
Diabetes Federation (IDF, www.eatlas.idf.org); the global diabetes epidemic is projected to
affect 7% of the world's adult population by 2025 as developing countries embrace bad health
habits associated with affluence. Every year, 7 million people are afflicted with diabetes. The
5. IDF estimates that diabetes already affects 387 million across the world, up from just 30 million
twenty years ago. IDF experts reported that diabetes is emerging as one of the chief public
health challenges of the 21st century, especially in developing nations.
Physicians sometimes screen for autoantibodies to insulin or beta cells. The antibodies
indicate a very high risk for developing Type 1 diabetes and can be present up to eight years
before symptoms develop. According to the American Diabetes
Association, four autoantibodies are markers of beta cell autoimmunity in
type 1 diabetes: islet cell antibodies (ICA, against cytoplasmic proteins in
the beta cell), antibodies to glutamic acid decarboxylase (GAD-65),
insulin autoantibodies (IAA), and IA-2A antibodies to protein tyrosine
phosphatase. Autoantibodies against GAD-65 are found in 80% of type 1
diabetics at clinical presentation.
Hepatitis
Hepatitis B virus (HBV) is a DNA virus that is transmitted by percutaneous or
permucosal exposure to infectious blood, blood products, or other body fluids. Perinatal
transmission is also possible. HBV is a complex structure with three distinct antigens: the surface
antigen, the core antigen and the e-antigen. Each antigen has a corresponding antibody that may
be elicited during an attack of acute viral hepatitis. These antibodies can be detected in the serum
of individuals with prior experience to the antigenic virus. Hepatitis C is a viral infection that
can create liver inflammation. Approximately 3.2 million people carry the virus in the U.S.
Roughly 16,600 deaths were attributed to hepatitis C in 2010. As many as 20% of those infected
with chronic hepatitis C will develop cirrhosis.
Hepatitis C virus (HCV) is an RNA virus that is primarily transmitted percutaneously. Other
routes of transmission are sexual or perinatal. About 40% of cases have no known source. Alere
offers an expansive infectious disease test menu that includes POC tests for influenza A & B,
respiratory syncytial virus (RSV), strep throat, pneumonia, C. difficile, mononucleosis, HIV,
herpes simplex virus (HSV-2), hepatitis C (HCV), hepatitis B (HBV), malaria, Lyme disease,
Chlamydia, H. pylori, rubella, and other infectious diseases. Alere also provides laboratory
immunoassays, including indirect fluorescent antibody (IFA) format assays and ELISA format
assays.
This White Paper is based
on results from Kalorama
Information's study:
The World Market for
Point of Care Diagnostics
http://www.kaloramainform
ation.com/Point-Care-POC-
9030928/
6. The World Market for Point of
Care (POC) Diagnostics
The World Market for Point of Care (POC) Diagnostics presents
the most current and authoritative analysis of the POC diagnostics
industry and the role it plays in medical practice. This report takes
an in-depth look at the POC diagnostic testing market, both
professional and self-testing. The report provides exclusive market
sizing and growth projections for the following POC market
segments:
• Blood Glucose Tests
• Blood and Electrolytes Testing Market
• Rapid Coagulation
• Rapid Cardiac Markers
• Substance Abuse Testing
• Pregnancy and Fertility Testing
• Colon Cancer Screening/Fecal Occult Blood Testing
• Infectious Disease Testing
• Cholesterol Testing
• Cancer Testing
• Urine Strip Testing
• Miscellaneous POC Testing
Who are the top companies in the market? What types of point of care testing is selling fastest? What
disease areas will drive near-patient forward? Is POC earning its place in clinical practice? How is home
testing progressing? These questions and more are addressed in Kalorama
Information’s report. Past editions of the report have long been used by top
point of care test makers to conduct business planning.
The report’s geographic scope is worldwide with information for specific
geographical regions, world demographics, and other general issues
affecting the market. All market data pertain to the world market at the
manufacturers’ level. The market includes manufacturer tests excluding
services. The base year for data is 2014.
Historical data is provided for the years 2012 and 2014, with forecast data
provided for 2014 through 2019. Compound annual growth rates (CAGRs)
are provided for 2014-2019 periods for each segment covered. Competitive
analysis is provided for the year 2014.
7. Market analysis of the global POC testing market includes:
• Market Overview
• Market Analysis by Product Categories
• Market Analysis by Subcategory: POC Professional Testing, POC Self-Testing
• Market Analysis by Country: United States, Germany, France, UK, Switzerland, Japan,
China, India
• Market Conclusions
• Competitive Analysis
• Trend-Reimbursement Challenges
• Trend-Competition
• Trend-POC and Biosensors
• Trend-POC Connectivity
• Trend-The Emergence of Non-invasive Technologies
Among the top and/or innovative competitors discussed within the report's
Corporate Profiles:
• Abaxis
• Abbott Labs
• Accriva
• ACON
• Alere
• Arkray
• Beckman Coulter
• bioMerieux
• Church & Dwight
• Eiken Chemical
• EKF Diagnostics
• Enterix
• Helena Labs
• Insight Pharmaceutical
• Instrumentation Laboratories
• LifeScan
• Macherey-Nagel
• Meridian BioScience
• Nova Biomedical
• OPKO Health
• OraSure
• Ortho Clinical Diagnostics
• Polymed Therapeutics
• Polymer Technologies
• Quidel
• Radiometer Medical
• Response Biomedical
• Roche Diagnostics
• Siemens Healthcare
• Sysmex
• Trinity Biotech
FOR MORE INFORMATION OR TO ORDER
http://www.kaloramainformation.com/Point-Care-POC-9030928/